Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 9/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29879003 | 1.00 | TRPV4 (0.46) | TRPV4LIPENR3C1PGRROCK2 | |
| SCHEMBL29140783 | 0.89 | LIPE (0.35) | TRPV4LIPEROCK2LPLLIPG | |
| SCHEMBL1485098 | 0.87 | LIPE (0.35) | TRPV4LIPEROCK2LPLLIPG | |
| SCHEMBL31441573 | 0.87 | LIPE (0.35) | TRPV4LIPEROCK2LPLLIPG | |
| SCHEMBL30292561 | 0.81 | APLNR (0.38) | LIPEROCK2LPLLIPG | |
| SCHEMBL1484864 | 0.81 | APLNR (0.38) | LIPEROCK2LPLLIPG | |
| SCHEMBL29760199 | 0.81 | LIPE (0.44) | LIPEROCK2LPLLIPG | |
| SCHEMBL29108916 | 0.81 | LIPE (0.44) | LIPEROCK2LPLLIPG | |
| Water SCHEMBL2513501 | 0.80 | APLNR (0.37) | LIPEROCK2LPLLIPG | |
| SCHEMBL365301 | 0.79 | L3MBTL1 (0.36) | LIPELPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-12570634-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2026-03-10 | — | — | US | disclosed |
| US-20250026754-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240190839-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11739077-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-29 | — | — | US | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3070086-B1 | AZAINDOLE DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-11-21 | — | — | EP | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-9782392-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9676773-B2 | Azaindole derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20170119743-A1 | AZAINDOLE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20160340353-A1 | AZAINDOLE DERIVATIVE | TAIHO PHARMARCEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-3070086-A1 | AZAINDOLE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | TRPV4 4635/4885LIPE 4882/4885NR3C1 2404/4885 |
| US-20170119743-A1 | AZAINDOLE DERIVATIVE | JAK3, JAK1, JAK2 | TRPV4 4633/4885LIPE 4809/4885NR3C1 286/4885 |
| US-20250026754-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | TRPV4 4879/4885LIPE 1471/4885NR3C1 3875/4885 |
| US-20240190839-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | TRPV4 4879/4885LIPE 1404/4885NR3C1 4152/4885 |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | TRPV4 199/4885LIPE 3228/4885NR3C1 1484/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | TRPV4 159/4885LIPE 2492/4885NR3C1 912/4885 |
| US-20160340353-A1 | AZAINDOLE DERIVATIVE | JAK3, JAK1, JAK2 | TRPV4 3584/4885LIPE 4766/4885NR3C1 146/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | TRPV4 257/4885LIPE 3357/4885NR3C1 1577/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | TRPV4 257/4885LIPE 3357/4885NR3C1 1577/4885 |
| US-11739077-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | USP1, USP2, USP28 | TRPV4 4879/4885LIPE 1404/4885NR3C1 4152/4885 |
| US-12570634-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | USP1, USP2, USP3 | TRPV4 4796/4885LIPE 3450/4885NR3C1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.